Alcon Completes Acquisition of BELKIN Vision

Alcon has finalized its acquisition of BELKIN Vision, marking a significant expansion of its glaucoma treatment offerings. The acquisition, valued at $81M upfront, with potential additional payments up to $385M contingent on sales milestones, includes BELKIN Vision’s innovative Direct Selective Laser Trabeculoplasty (DSLT) technology.

This acquisition strengthens Alcon’s existing portfolio, which includes pharmaceutical drops and implantables like the Hydrus® Microstent, by adding a first-line laser therapy option.

Advancing SLT Adoption Globally

"As a therapy with significant advantages for patients and practices alike, we believe our newly acquired DSLT technology will play a crucial role in advancing the adoption of Selective Laser Trabeculoplasty (SLT) as a first-line treatment in glaucoma management," said Sean Clark, President, Global Surgical Franchise, Alcon. "We are committed to expanding access to this transformative technology globally, addressing unmet needs in glaucoma treatment."

Clinical Evidence and Effectiveness

Studies such as the LiGHT trial have demonstrated SLT’s effectiveness and cost-efficiency in treating open-angle glaucoma (OAG) and ocular hypertension (OHT) by reducing the reliance on intraocular pressure (IOP) lowering medications and surgeries. The GLAUrious study further validated DSLT’s ability to effectively lower IOP with a proven safety profile, utilizing proprietary eye-tracking technology for precise treatment delivery without the need for manual aiming or a gonio lens.

"Despite the evidence supporting SLT as a primary therapy for glaucoma, practical barriers have hindered widespread adoption," noted Nathan M. Radcliffe, M.D. "DSLT represents a significant step toward overcoming these challenges, enhancing access to laser therapy and reshaping perceptions of efficiency and patient comfort."

Regulatory Status and Future Plans

Currently approved in the European Union (E.U.) and the United Kingdom (U.K.), DSLT has received 510(k) Clearance from the U.S. Food & Drug Administration, with plans for U.S. availability by the end of 2024. Alcon intends to integrate DSLT into its Alcon Vision Suite ecosystem, ensuring comprehensive support and training to meet the needs of healthcare providers and patients alike.